Shiny K. Kajal/LinkedIn
Mar 3, 2026, 17:04
Shiny K Kajal: Therapeutic Apheresis Is Redefining the Clinical Scope of Transfusion Medicine
Shiny K Kajal, Senior Resident at Adesh University, shared a post on LinkedIn:
“Post 29 – When most people think of transfusion medicine, they think of blood bags and compatibility testing.
But modern Immunohematology and Blood Transfusion goes far beyond that.
Therapeutic Apheresis allows selective removal of disease-causing components directly from circulation – offering rapid clinical benefit in several critical conditions.
Key Apheresis Modalities
- Therapeutic Plasma Exchange (TPE) – Removal of pathogenic plasma components
- Red Cell Exchange – Replacement of abnormal erythrocytes
- Leukapheresis – Rapid cytoreduction in leukocytosis
- Plateletpheresis – Control of extreme thrombocytosis
- LDL Apheresis – Removal of atherogenic lipoproteins
From autoimmune diseases to hematologic emergencies, therapeutic apheresis is redefining the clinical scope of transfusion medicine.
Not just transfusing blood — but therapeutically transforming it.”
Stay updated with Hemostasis Today.
-
Jul 26, 2026, 08:51Dayita Banerjee: Presenting New Insights in Fibrinolysis Research at ISTH 2026
-
Jul 26, 2026, 08:39Roshni Kulkarni: The Human Face of Postpartum Hemorrhage
-
Jul 26, 2026, 08:14Atahar imam Hasan: Universal Artificial Blood and the Future of Trauma Care
-
Jul 26, 2026, 07:40Maha Othman: Leading Scientific Collaboration Across Hemostasis at ISTH 2026
-
Jul 26, 2026, 07:20Pablo Corral: Why Should Dyslipidemia Be Any Different?
-
Jul 26, 2026, 06:46Marios Georgakis: Largest GWAS of Transient Ischemic Attacks Reveals New Genetic Insights into Stroke Risk
-
Jul 26, 2026, 06:40Aaron Iding: From Virtual Meetings to Meaningful Connections at ISTH 2026
-
Jul 26, 2026, 06:36How Stroke Services Have Evolved Over the Past 8 Years in Kazakhstan – International Journal of Stroke
-
Jul 26, 2026, 06:31Leonardo Roever: Non-LDL Biomarkers and The Potential Future Applications for 2ry Stroke Prevention